Aetna Pulsed Radiofrequency Coverage Policy (CPB 0735) — What Billing Teams Need to Know in 2025
TL;DR: Aetna, a CVS Health company, modified CPB 0735 for pulsed radiofrequency, effective October 31, 2025. The policy classifies pulsed radiofrequency as experimental, investigational, or unproven across all 73 listed indications — meaning no covered path exists for this procedure under Aetna billing guidelines.
This update is a blanket denial policy. If your practice performs pulsed radiofrequency for any indication — low back pain, trigeminal neuralgia, occipital neuralgia, chronic knee pain, diabetic peripheral neuropathy, or anything else — Aetna will not reimburse it. There are no exceptions and no carve-outs for specific patient populations. The effective date of October 31, 2025 is already past. If you haven't updated your billing workflows, you're already at risk.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Pulsed Radiofrequency — CPB 0735 |
| Policy Code | CPB 0735 |
| Change Type | Modified |
| Effective Date | October 31, 2025 |
| Impact Level | High |
| Specialties Affected | Pain management, interventional spine, neurology, orthopedic surgery, physical medicine & rehabilitation, urology, gynecology |
| Key Action | Stop submitting pulsed radiofrequency claims to Aetna immediately — flag all active cases and notify referring providers |
Aetna Pulsed Radiofrequency Coverage Policy and Medical Necessity Requirements 2025
The Aetna pulsed radiofrequency coverage policy under CPB 0735 is absolute: Aetna does not consider pulsed radiofrequency medically necessary for any indication. That's not an overstatement — it's what the policy says.
Pulsed radiofrequency (PRF) delivers short bursts of radiofrequency energy to nerve tissue. It differs from conventional continuous radiofrequency ablation, which thermally destroys nerve tissue. PRF doesn't generate the same tissue-damaging heat, which is why clinicians use it when they want neuromodulation without permanent lesioning. The clinical logic has always been appealing. Aetna's position is that the evidence hasn't caught up.
Under CPB 0735, Aetna finds no established effectiveness for PRF across any of the 73 indications listed in the policy. CPB 0735 classifies pulsed radiofrequency as experimental and unproven for all listed indications. The policy does not describe coverage exceptions or appeal pathways for this procedure.
If your pain management or interventional spine practice treats Aetna members, this is the coverage policy that governs every PRF claim you submit. The policy does not describe a prior authorization pathway for coverage — consult your Aetna provider agreement and plan documents for PA requirements specific to your contract.
Aetna Pulsed Radiofrequency Exclusions and Non-Covered Indications
This section is the core of CPB 0735. Aetna classifies PRF as experimental, investigational, or unproven across all 73 named indications. The breadth is striking. It covers essentially every clinical context where PRF is currently used or studied.
The full list includes conditions across every body region and specialty. Pain management practices will recognize these immediately:
| # | Excluded Procedure |
|---|---|
| 1 | Spinal and radicular pain: Cervical radicular pain, chronic lumbosacral radicular pain, discogenic pain, lumbar herniated nucleus pulposus, lumbo-sacral radicular syndrome, neck pain, low back pain, thoracic pain, zygapophyseal joint pain |
| 2 | Headache and facial pain: Chronic migraine, cervicogenic headache, trigeminal neuralgia, glossopharyngeal neuralgia, occipital neuralgia, infraorbital neuralgia, idiopathic supraorbital neuralgia, ophthalmic neuralgia, face and head pain |
| 3 | Peripheral neuropathy: Diabetic peripheral neuropathy, idiopathic axonal polyneuropathy, peripheral neuralgia, peripheral post-traumatic neuropathic pain, post-herpetic neuralgia, sural neuralgia, lower extremity neuralgia |
| 4 | Joint and musculoskeletal pain: Facet and sacroiliac joint arthropathy, chronic knee pain, osteoarthritis of the knee, chronic hip pain, frozen shoulder, hemiplegic shoulder pain, metatarsalgia, metatarso-phalangeal joint pain, trapezio-metacarpal joint pain, periscapular pain, plantar fasciitis |
| 5 | Pelvic, urologic, and gynecologic pain: Pudendal neuralgia, pelvic pain, interstitial cystitis, orchalgia, post-surgical orchialgia, perineal pain, chronic perineal pain, vulvodynia, vaginismus, urinary urgency and hesitancy |
| 6 | Neuromatous and entrapment pain: Morton's neuroma, tarsal tunnel syndrome, carpal tunnel syndrome, meralgia paresthetica, inguinal neuralgia, abdominal cutaneous nerve entrapment syndrome, intercostal neuralgia after lung cancer surgery, intercostobrachial neuralgia in post-mastectomy pain syndrome |
| 7 | Other: Chronic pain following inguinal herniotomy, reflex sympathetic dystrophy/complex regional pain syndrome, myofascial pain syndrome, stump pain, tinnitus, palmar hyperhidrosis, ventricular arrhythmias, sensory deficits following stroke, striae rubra, pain associated with tumors involving peripheral nerves, zoster-related pain, post-herpetic itch, premature ejaculation, orthodontically-induced inflammatory root resorption |
Two specific PRF devices also carry explicit non-covered designations:
| # | Excluded Procedure |
|---|---|
| 1 | Stimpod NMS460 nerve stimulator (Xavant Technology) — experimental and unproven |
| 2 | Wearable pulsed radiofrequency therapy device for post-amputation pain — experimental and unproven |
Two combination approaches are also excluded:
| # | Excluded Procedure |
|---|---|
| 1 | Combined ganglion impar block and PRF for pudendal neuralgia |
| 2 | Combined platelet-rich plasma (PRP) to the Gasserian ganglion and PRF for trigeminal neuralgia |
If your practice uses the Stimpod or any wearable PRF device, code those separately from conventional PRF — but understand that both paths lead to the same claim denial outcome with Aetna.
The real issue here isn't whether any of these indications might respond to PRF in individual patients. The issue is that Aetna has made an institutional determination that the published evidence doesn't support coverage for any of them.
Coverage Indications at a Glance
| Indication | Status | Notes |
|---|---|---|
| Cervical radicular pain | Not Covered — Experimental | |
| Chronic lumbosacral radicular pain | Not Covered — Experimental | |
| Low back pain | Not Covered — Experimental | |
| Trigeminal neuralgia | Not Covered — Experimental | Combined PRP + PRF also excluded |
| Occipital neuralgia | Not Covered — Experimental | |
| Diabetic peripheral neuropathy | Not Covered — Experimental | Applies across all diabetes mellitus types |
| Post-herpetic neuralgia | Not Covered — Experimental | Zoster-related pain also excluded |
| Chronic knee pain / Osteoarthritis of knee | Not Covered — Experimental | |
| Chronic hip pain | Not Covered — Experimental | |
| Facet and sacroiliac joint arthropathy | Not Covered — Experimental | See CPB 0016 for conventional RF denervation |
| Morton's neuroma | Not Covered — Experimental | |
| Pudendal neuralgia | Not Covered — Experimental | Combined ganglion impar block + PRF also excluded |
| Complex regional pain syndrome / RSD | Not Covered — Experimental | |
| Plantar fasciitis | Not Covered — Experimental | |
| Interstitial cystitis | Not Covered — Experimental | |
| Vulvodynia | Not Covered — Experimental | |
| Frozen shoulder (adhesive capsulitis) | Not Covered — Experimental | |
| Chronic migraine | Not Covered — Experimental | |
| Tinnitus | Not Covered — Experimental | |
| Ventricular arrhythmias | Not Covered — Experimental | |
| Stimpod NMS460 (Xavant Technology) | Not Covered — Experimental | Device-level exclusion |
| Wearable PRF for post-amputation pain | Not Covered — Experimental | Device-level exclusion |
| All other listed indications (73 total) | Not Covered — Experimental | No exceptions in CPB 0735 |
Aetna Pulsed Radiofrequency Billing Guidelines and Action Items 2025
The effective date of October 31, 2025 has already passed. These action items are urgent, not prospective.
| # | Action Item |
|---|---|
| 1 | Audit all pulsed radiofrequency claims submitted to Aetna on or after October 31, 2025. Pull every PRF claim in your billing system. Flag any that went out without denial screening. If you submitted and haven't received a response, expect denial. |
| 2 | Update your charge capture to flag PRF claims for Aetna members before submission. Your billing team should add a review stop in your practice management system. Any CPT code associated with PRF for Aetna-insured patients should trigger a review flag before the claim goes out. |
| 3 | Notify referring providers and ordering physicians immediately. Pain management practices that receive referrals need to tell those referring providers that PRF is non-covered under Aetna. If a referring orthopedic surgeon or neurologist is sending Aetna members for PRF, they need to know the reimbursement picture before they write that order. |
| 4 | Separate PRF billing from conventional radiofrequency ablation claims. Conventional radiofrequency facet denervation has a separate policy — CPB 0016. That procedure may be covered under different criteria. Don't let a PRF denial contaminate a legitimate RF ablation claim. Review your charge capture to make sure these procedures are coded and tracked separately. |
| 5 | Review any financial agreements or advance beneficiary notice equivalents for Aetna members. Since PRF is categorically non-covered — patients who want PRF are paying out of pocket. Make sure your front desk and financial counselors understand this. Document patient consent for self-pay PRF services properly before the procedure. |
| 6 | If you're billing for the Stimpod NMS460 or any wearable PRF device, treat those as separate line items with the same non-covered expectation. Bundling or embedding device charges in a broader procedure note won't change the outcome. Aetna's policy excludes the device and the procedure. |
| 7 | Talk to your compliance officer before submitting any PRF claim to Aetna. If your practice has been billing PRF under codes that might overlap with covered procedures, or if you're unsure how your specific CPT coding maps to CPB 0735, get a compliance review before the next billing cycle. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Pulsed Radiofrequency Under CPB 0735
The CPB 0735 Aetna system policy does not list specific CPT or HCPCS procedure codes in the provided policy data. Pulsed radiofrequency billing typically uses CPT codes from the nerve block and neurolytic injection families — work with your billing consultant to identify the exact codes your practice uses for PRF and flag them all as non-covered for Aetna.
Key ICD-10-CM Diagnosis Codes Tracked Under CPB 0735
The policy tracks 508 ICD-10-CM codes. The table below covers the primary diagnosis categories. Every code in this list represents a condition for which Aetna considers PRF experimental — billing PRF with any of these as the primary diagnosis will result in a claim denial.
| Code | Description |
|---|---|
| B02.21 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| B02.22 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| B02.23 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| B02.24 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| B02.25 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| B02.26 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| B02.27 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| B02.28 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| B02.29 | Zoster with other nervous system involvement (post-herpetic neuralgia) |
| D21.0–D21.9 | Other benign neoplasms of connective and other soft tissue (neuromatous pain) |
| D36.10–D36.17 | Benign neoplasm of peripheral nerves and autonomic nervous system (neuromatous pain) |
| E08.40–E08.49 | Diabetes mellitus due to underlying condition with neurological complications |
| E09.40–E09.49 | Drug or chemical induced diabetes mellitus with neurological complications |
| E10.40–E10.49 | Type 1 diabetes mellitus with neurological complications |
| E11.40–E11.49 | Type 2 diabetes mellitus with neurological complications |
| E13.40–E13.49 | Other specified diabetes mellitus with neurological complications |
| F52.4 | Premature ejaculation |
| G43.701 | Chronic migraine without aura, not intractable |
| G43.702 | Chronic migraine without aura, not intractable |
The full policy tracks 508 ICD-10-CM codes across all 73 excluded indications. Use PayerPolicy's CPB 0735 policy page to pull the complete code list — it's searchable by code range and diagnosis category.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.